Caredx reports inducement grant under nasdaq listing rule 5635(c)(4)

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on october 8, 2024, caredx granted to jing huang, the company's newly appointed chief data and ai officer, 15,547 restricted stock units (“rsus”) and an option to purchase 22,248 shares.
CDNA Ratings Summary
CDNA Quant Ranking